公开(公告)号：US12098199B2

公开(公告)日：2024-09-24

申请号：US17522284

申请日：2021-11-09

申请人： CRAGE medical Co., Limited

发明人： Huamao Wang ,  Bo Song ,  Xiumei Cai

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K48/00 ,  C07K14/705 ,  C07K14/725 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/867 ,  A61K35/12

CPC分类号： C07K16/28 ,  A61K35/17 ,  A61K48/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/867 ,  A61K2035/124 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70

摘要： Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

公开(公告)号：US11957715B2

公开(公告)日：2024-04-16

申请号：US16954912

申请日：2018-12-19

申请人： MILTENYI BIOTEC B.V. & CO. KG

发明人： Rafijul Bari ,  Markus Granzin ,  Wing Leung ,  Nina Moker ,  Volker Huppert

IPC分类号： A61K35/17 ,  C07K14/54 ,  C07K14/545 ,  C07K14/55 ,  C12N15/867

CPC分类号： A61K35/17 ,  C07K14/5443 ,  C07K14/545 ,  C07K14/55 ,  C12N15/867 ,  C07K2319/85 ,  C12N2740/13044

摘要： The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.

公开(公告)号：US20230287116A1

公开(公告)日：2023-09-14

申请号：US18319638

申请日：2023-05-18

申请人： Asclepius (Suzhou) Technology Company Group Co., Ltd.

发明人： Huashun LI ,  Baolei WANG ,  Kunkun HAN

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783 ,  C12N15/867

CPC分类号： C07K16/2803 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C12N5/0646 ,  C12N15/867 ,  A61K38/00

摘要： The present disclosure relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

公开(公告)号：US11697685B2

公开(公告)日：2023-07-11

申请号：US16700401

申请日：2019-12-02

申请人： Asclepius (Suzhou) Technology Company Group Co., Ltd.

发明人： Huashun Li ,  Baolei Wang ,  Kunkun Han

IPC分类号： C07K16/28 ,  C07K14/705 ,  C12N5/0783 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/867 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C12N5/0646 ,  C12N15/867 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N5/0636 ,  C12N2510/00

摘要： The present invention relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

公开(公告)号：US20230130635A1

公开(公告)日：2023-04-27

申请号：US18085751

申请日：2022-12-21

申请人： HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZE ,  SIRION BIOTECH GMBH

发明人： Natasa ANASTASOV ,  Ines HOFIG ,  Christian THIRION

IPC分类号： C12N15/86 ,  C12N15/867 ,  A61K48/00

摘要： The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa. Further, the invention relates to the use of a poloxamer as defined herein, optionally in combination with a polycationic substance as defined herein, for transducing a target cell with a retroviral vector and a kit comprising a retroviral vector, a poloxamer as defined herein and, optionally, instructions for use.

公开(公告)号：US20220363751A1

公开(公告)日：2022-11-17

申请号：US17522284

申请日：2021-11-09

申请人： Cafa Therapeutics Limited

发明人： Huamao WANG ,  Bo SONG ,  Xiumei CAI

IPC分类号： C07K16/28 ,  A61K48/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/867 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705

摘要： Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

公开(公告)号：US20220184119A1

公开(公告)日：2022-06-16

申请号：US17310463

申请日：2020-02-05

申请人： BIONTECH CELL & GENE THERAPIES GMBH

发明人： Ugur SAHIN ,  Petra OEHM ,  Benjamin RENGSTL ,  Katharina REINHARD ,  Kristina MICHEL

IPC分类号： A61K35/17 ,  A61K31/7105 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C12N15/62 ,  C12N15/867

摘要： The present disclosure relates to a chimeric antigen receptor (CAR) showing highly specific and sensitive recognition of CLDN6 expressing target cells as well as a high potential for survival and repetitive stimulation of CAR T cells.

公开(公告)号：US11345734B2

公开(公告)日：2022-05-31

申请号：US15577378

申请日：2016-05-31

申请人： AUTOLUS LIMITED

发明人： Martin Pulé ,  Shaun Cordoba ,  Simon Thomas ,  Khai Kong

IPC分类号： C12N5/0783 ,  C07K14/725 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N15/867

摘要： The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.

公开(公告)号：US11325948B2

公开(公告)日：2022-05-10

申请号：US17110028

申请日：2020-12-02

申请人： Exuma Biotech Corp.

发明人： Gregory Ian Frost ,  James Joseph Onuffer, Jr. ,  Ghiabe H. Guibinga ,  Farzad Haerizadeh ,  Frederic Vigant ,  Anirban Kundu

IPC分类号： C12N15/867 ,  C07K14/005 ,  C12N15/86 ,  C07K14/705 ,  C07K16/28 ,  C07K14/725 ,  C07K14/54 ,  A61K47/69 ,  A61K35/17 ,  C12N7/00 ,  A61K38/00 ,  A61K39/00

摘要： The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

公开(公告)号：US20220026414A1

公开(公告)日：2022-01-27

申请号：US17299034

申请日：2019-12-06

申请人： Merck Sharp & Dohme Corp.

发明人： Junming Yie

IPC分类号： G01N33/50 ,  C12N15/867 ,  C12N9/02

摘要： A functional cell-based assay for use as a bioidentity assay for insulin or insulin analogs is described. The assay may be used as a replacement of the rabbit blood sugar method disclosed in USP Insulin Assays.